Biovica: A considerable boost in the clinical use of DiviTum tests - Redeye

Biovica records IVD test sales in Q1 of SEK 0.62m, which is 50% above the previous quarter (Q4) and >100% above the earlier quarter (Q3), despite the late spring reorganisation of the US sales force. The RUO sales relating to pharma had a modest contribution. Still, in this segment, Biovica has already established a positive trend, as illustrated by the recent Master Service agreement win, bringing the total to 15 (with five different accounts) with an initial sales contribution of SEK 0.75m. Biovica recently also secured a directed new share issue of units, bringing SEK 16.4m without rebate to the recent share price.

Länk till analysen i sin helhet: https://www.redeye.se/research/1039557/biovica-a-considerable-boost-in-the-clinical-use-of-divitum-tests?utm_source=finwire&utm_medium=RSS